These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 25224029

  • 1. Prevaccination antibody screening and immunization program for healthcare personnel against measles, mumps, rubella, and varicella in a Japanese tertiary care hospital.
    Kanamori H, Tokuda K, Ikeda S, Endo S, Ishizawa C, Hirai Y, Takahashi M, Aoyagi T, Hatta M, Gu Y, Yano H, Weber DJ, Kaku M.
    Tohoku J Exp Med; 2014 Oct; 234(2):111-6. PubMed ID: 25224029
    [Abstract] [Full Text] [Related]

  • 2. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M, Broder KR, Temte JL, Snider DE, Seward JF, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2010 May 07; 59(RR-3):1-12. PubMed ID: 20448530
    [Abstract] [Full Text] [Related]

  • 3. Seroprevalence survey of measles, rubella, varicella, and mumps antibodies in health care workers and evaluation of a vaccination program in a tertiary care hospital in Japan.
    Asari S, Deguchi M, Tahara K, Taniike M, Toyokawa M, Nishi I, Watanabe M, Iwatani Y, Makimoto K.
    Am J Infect Control; 2003 May 07; 31(3):157-62. PubMed ID: 12734521
    [Abstract] [Full Text] [Related]

  • 4. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
    Marshall GS, Senders SD, Shepard J, Twiggs JD, Gardner J, Hille D, Hartzel J, Valenzuela R, Stek JE, Helmond FA.
    Hum Vaccin Immunother; 2016 Aug 02; 12(8):2188-2196. PubMed ID: 27149048
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH, Hirai HW, Tsoi KK.
    Expert Rev Vaccines; 2015 Aug 02; 14(8):1149-57. PubMed ID: 26081133
    [Abstract] [Full Text] [Related]

  • 6. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A, Ergonul O, Aksaray S, Tuygun N, Esener H, Tanir G, Eren S, Baykam N, Guvener E, Dokuzoguz B.
    Am J Infect Control; 2006 Nov 02; 34(9):583-7. PubMed ID: 17097453
    [Abstract] [Full Text] [Related]

  • 7. Prevaccination screening of health-care workers for immunity to measles, rubella, mumps, and varicella in a developing country: What do we save?
    Alp E, Cevahir F, Gökahmetoglu S, Demiraslan H, Doganay M.
    J Infect Public Health; 2012 Apr 02; 5(2):127-32. PubMed ID: 22541258
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 02; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 9. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T, McIntyre P, Roberton D, Descamps D.
    Vaccine; 2002 Dec 13; 21(3-4):281-9. PubMed ID: 12450703
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 13; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 11. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM, Baker L, Starr SE, Levine BL, Books E, Plotkin SA.
    Pediatrics; 1986 Oct 13; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [Abstract] [Full Text] [Related]

  • 12. Self-reported histories of disease and vaccination against measles, mumps, rubella and varicella in health care personnel in Japan.
    Kumakura S, Onoda K, Hirose M.
    J Infect Chemother; 2014 Mar 13; 20(3):194-8. PubMed ID: 24462433
    [Abstract] [Full Text] [Related]

  • 13. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Jul 13; 25(7):615-22. PubMed ID: 16804432
    [Abstract] [Full Text] [Related]

  • 14. Influences on immunization rates: Vaccination coverage of mumps, measles, rubella and varicella before and after the STIKO intervention 2011 - A retrospective study.
    Sanftenberg L, Schrörs HJ, Schelling J.
    Vaccine; 2016 Jul 25; 34(34):3938-41. PubMed ID: 27318420
    [Abstract] [Full Text] [Related]

  • 15. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V.
    Cochrane Database Syst Rev; 2020 Apr 20; 4(4):CD004407. PubMed ID: 32309885
    [Abstract] [Full Text] [Related]

  • 16. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
    Durando P, Esposito S, Bona G, Cuccia M, Desole MG, Ferrera G, Gabutti G, Pellegrino A, Salvini F, Henry O, Povey M, Marchetti F.
    Vaccine; 2016 Aug 05; 34(36):4278-84. PubMed ID: 27423382
    [Abstract] [Full Text] [Related]

  • 17. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G, Berton O, Singh T, Knuf M, Bonanni P.
    Expert Rev Vaccines; 2023 Aug 05; 22(1):764-776. PubMed ID: 37642012
    [Abstract] [Full Text] [Related]

  • 18. [Seroprevalence of measles, rubella, mumps and varicella in health workers in the Community of Madrid].
    Rodríguez ML, Martínez D, Santos-Sancho JM, Borda JR, Orero A.
    Rev Esp Quimioter; 2014 Jun 05; 27(2):98-101. PubMed ID: 24940889
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the seroprevalence of measles, rubella, mumps, and varicella and the requirement for additional vaccination based on the JSIPC guidelines among emergency medical technicians at eight fire stations in Narita, Japan: a project review.
    Hase R, Niiyama Y, Mito H.
    Hum Vaccin Immunother; 2022 Dec 31; 18(1):1989922. PubMed ID: 34756159
    [Abstract] [Full Text] [Related]

  • 20. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
    Ödemiş Í, Köse Ş, Akbulut Í, Albayrak H.
    Rev Esp Quimioter; 2019 Dec 31; 32(6):525-531. PubMed ID: 31642641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.